GeneDx Holdings Corp. Q4 FY2024 earnings call

Key Points

• 2024 was remarkable with revenues exceeding $95M in Q4 and 70% gross margin. 2025 guidance set for $350M-$360M revenue with at least 30% growth in exome/genome volume/revenue.
• Technology enables efficient model, reducing healthcare inefficiency; rare disease economic burden is ~$1T annually, and GeneDx helps alleviate this.
• Adjusted gross profit in Q4 was $66.9M, up 106% YOY and 36% sequentially, with adjusted gross margin at 70%.
• Launched ultraRapid whole genome sequencing (48-hour turnaround) for NICU, expanded enterprise sales team, and enhanced Epic Aura integration.
• Expanded sales team, hired 25 inside sales reps to offload admin burden, focusing on customer experience to drive stickiness and same-store sales.

In the fourth quarter, exome and genome revenues were $78.8 million, growing 101% year-over-year and 31% sequentially, contributing $78.8 million and accounting for 38% of all tests in Q4 (up from 27% a year ago). Over 20,000 flagship exome and genome tests were delivered, up 32% year-over-year and 7% sequentially. Hereditary cancer is a non-core fit and will be exited in 2025.

2025 Guidance

• Revenue range: $350M to $360M, with at least 30% growth in exome and genome volume and revenue.
• Adjusted gross margin expected to be between 65% and 67% for full year 2025.
• Committed to maintaining profitability, with Q1 near breakeven and ramping in later quarters.
• Exiting hereditary cancer in 2025 to focus on core exome and genome growth.

Risks

• Reimbursement challenges: Nearly half of tests still face denials; need to continue refining processes to minimize denials.
• Competitive landscape: Potential for competitors to enter the market, though GeneDx's data asset and customer experience act as moats.
• Regulatory/policy uncertainty: Changes in state/federal policies could impact coverage and reimbursement for exome/genome testing.

Q: Color on implied price assumption for 2025, pricing outlook A: Kevin Feeley said rates are stable with room to go higher, team refining processes to avoid denials, and guidance data-dependent.

Q: OpEx leverage, EBITDA and cash flow in 2025 A: Kevin Feeley mentioned step up in OpEx, e.g., $5M annual Epic investment, with Q1 near breakeven and ramping later.

Q: New opportunities in NICU and outpatient, magnitude A: Katherine Stueland said NICU and new outpatient indications (e.g., cerebral palsy, hearing loss) to ramp in H2 2025.

Q: Sales force expansion magnitude and cost A: Katherine Stueland said enterprise team expanded from 5 to 10, 25 inside sales reps hired, with investments to improve productivity.

Q: UltraRapid product, turnaround time vs legacy, pricing A: Katherine Stueland said ultraRapid is 48-hour vs legacy, higher price point for NICU dire cases, and aim to be competitive.

Q: Phasing of revenue, Q1 volume impact A: Kevin Feeley expected Q1 slightly above Q4, seasonal lag, but H2 ramp due to NICU and new indications.

Q: Programs/initiatives in 2025-2026, adult opportunity A: Katherine Stueland said PMO and innovation team focus on automation, adult opportunity in neurodegenerative, cardiac conditions.

Q: Hereditary cancer exit, gross margin profile A: Kevin Feeley said 2025 will lose vast majority of hereditary cancer contribution, margin profile around 40%.

Q: Epic Aura rollout, sites by end of year, revenue phasing A: Katherine Stueland said UNC first, others as fast followers, slow start in guide then H2 ramp.